Orthopaedic device firms adapt to hospital decision shifts emphasizing value and workflow integration

Small orthopaedic device makers are finding it harder to win hospital approval for new implants as health systems tighten their procurement processes and give greater weight to value analysis committees, cost control and operational fit.

The shift reflects a broader change in how hospitals buy high-cost devices. According to commentary from industry and clinical discussions at the NASS Innovation NetWORK Summit, the days when a persuasive surgeon could effectively drive adoptio...

n on their own are fading. Today, purchasing decisions are more likely to involve a multidisciplinary group that includes clinical leaders, administrators, supply chain teams, finance and nursing, each of whom may judge a product through a different lens.

That makes the first conversation crucial. Rather than leading with novelty, speakers at the summit urged companies to begin by understanding what problems the hospital is actually trying to solve. For a health system, that might mean reducing friction in the operating theatre, protecting workforce capacity, improving consistency across sites or strengthening financial performance. As Timothy Liesching, chief medical officer at BayCare Health System, put it: “Where many folks in this room are thinking about novelty, I’m thinking about reliability,” he said. “While you’re talking about product, I’m talking about workforce workflows.”

His remarks reflect a wider reality documented in studies of hospital procurement, which show a clear move away from ad hoc, surgeon-led choices and towards formalised, committee-based assessment. In practice, that means small companies must do more than demonstrate clinical promise. They need to show how a device fits existing workflows, what training it requires, how long implementation will take and how success will be measured once the first case is complete.

The financial case has become just as important as the clinical one. Hospital leaders now expect evidence on total device cost, reimbursement, procedure volume, operating theatre time and the possible effect on complications or revisions. Industry analysis of implant buying has also highlighted the importance of bundled-payment economics and platform lock-in, both of which can shape whether a new product is worth the disruption of switching from an incumbent system.

That is where value analysis committees have become central. Over the past two decades, these groups have grown more sophisticated, with hospitals and ambulatory surgery centres using them to align device selection with the modern care model’s demands for quality, efficiency and affordability. A recent review of hospital decision-making found that such committees are now a standard feature in the purchase of high-cost medical devices, especially orthopaedic implants, and that decisions increasingly depend on formal evidence rather than individual preference.

For manufacturers, that means relationships matter long before a formal review begins. A respected surgeon can still open the door, but approval usually depends on buy-in from a wider set of stakeholders. Companies that understand the priorities of finance, supply chain, operations and clinical leadership are better placed to shape their message and deal with objections before they harden.

Equally important is the implementation plan. Hospital leaders want to know what happens after the contract is signed. They expect clarity on training, learning curves, inventory handling and the point at which surgeons are likely to return to baseline efficiency. Several speakers advised companies to seek a limited pilot and agree in advance what a successful outcome would look like from the hospital’s perspective. Without that, an evaluation can become a vague exercise rather than a route to broader adoption.

Even strong clinical data will not be enough on its own. Hospitals are looking for partners that can help with reimbursement approvals, supply chain coordination and claims processing, not just product placement. Frequent check-ins during a pilot can help identify problems early and build trust, particularly when the goal is to move from a small trial to system-wide use.

For smaller orthopaedic companies, the message is clear: the sale no longer ends with the implant. It begins with an understanding of the hospital’s economics, workflows and internal decision-making, and succeeds only if the technology can prove it delivers value across the entire system.

Source: Noah Wire Services